
On April 15, in the case of The Association for Molecular Pathology vs. Myriad Genetics, Inc., the United States Supreme Court heard arguments questioning the legitimacy of patents on human genes. A genetic testing company, Myriad Genetics, has patent claims on two human genes that influence a person’s risk for breast cancer. Myriad is being sued by a conglomerate of physicians, scientists, and patients who argue that Myriad has illegitimately patented a product of nature. While the lawyers and Justices delved into the arcana of patent law and molecular biology, many of the rest of us were ... Read More




